Hodgkin Lymphoma Treatment Has Been Transformed by Immunotherapy. New Study Helps Explain Why

The go-to metaphor for cancer drugs known as immune checkpoint inhibitors is a brake-release lever — a means of setting loose an immune system attack on tumor cells. Helpful as it is, the analogy glosses over a highly complex mechanism involving multiple types of immune cells, cell receptors, signals, and responses — so intricate that … Read more

Hodgkin Lymphoma: The Latest in Treatment and Research

Chemotherapy has been the backbone of treatment for both untreated and relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). But treatment paradigms for cHL are changing. Immunotherapies that unmask cancer cells and make them vulnerable to our immune system, called immune checkpoint inhibitors (ICIs), were recently approved for relapsed and refractory cHL. Examples include PD-1 inhibitors such … Read more

Hodgkin Lymphoma Patient Aims to Lessen Cancer Stigma

Chloe Svolos is a social butterfly. When she isn’t working in the fundraising office for Dana-Farber’s Jimmy Fund, the 26-year-old is spending time with family, going out with friends, hanging out with her boyfriend, Luke, or traveling. She also recently completed treatment for lymphoma — so she’s still adjusting to her “new normal.” But in … Read more

Cancer Treatment: A Look at How It Has Evolved in 70 Years

In 1947, when Dana-Farber Cancer Institute founder Sidney Farber, MD, set out to find a drug treatment for childhood leukemia, cancer treatment took two forms – surgery to cut out cancerous masses, and radiation therapy to burn them out. Cancers that couldn’t be removed or irradiated – either because of their position in the body, because … Read more

Hodgkin Lymphoma Survivorship and Follow-Up Care

Adult Hodgkin lymphoma has one of the highest cure rates among all cancers. Still, the standard lymphoma therapies – including chemotherapy, radiation, surgery, and steroid therapy – may result in long-term side-effects beginning during treatment, and/or late-term effects arising years or decades after treatment. This is why check-ups and screenings are so important following treatment. … Read more

New Immunotherapy Therapy Approved for Lymphoma Patients

The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy. The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is … Read more

Voices Podcast – Season 2 Episode #1: Then and Now with Lymphoma and Breast Cancer Survivor Catherine Goff

When Catherine Goff was diagnosed with Hodgkin lymphoma while attending college in the 1970s, it was the shock of a lifetime. Less surprising – but still life-changing – was her later diagnosis with breast cancer, a common secondary cancer for patients like Goff who received high doses of radiation therapy to the chest. Between these … Read more

Non-Hodgkin Lymphoma and Hodgkin Lymphoma: What’s the Difference?

Hodgkin and non-Hodgkin lymphoma are the two main types of lymphoma, a cancer that affects the lymphatic system. The lymphatic system produces and transports white blood cells to fight infection. While they have many characteristics in common, there are some significant differences between Hodgkin and non-Hodgkin lymphoma, including the age groups they affect, how they … Read more

How a Cure for Hodgkin Lymphoma Changed the Course of Cancer Treatment

To mark its 50th anniversary, the American Society of Clinical Oncology (ASCO) invited physicians, patients, and the public to name the most important advances in clinical cancer research in the past half century. From more than 2,000 responses, the top choice was a cure for advanced Hodgkin lymphoma developed by scientists at the National Cancer … Read more

Hodgkin Lymphoma: Five Things You Need to Know

Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the Reed-Sternberg cell.

Arnold Freedman, MD, clinical director of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answers some questions about the disease:

Read more